AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 169.89 |
Market Cap | 9.12B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 8 |
PE Ratio (ttm) | 22.29 |
Forward PE | n/a |
Analyst | Hold |
Ask | 179.52 |
Volume | 1,708,280 |
Avg. Volume (20D) | 674,709 |
Open | 179.87 |
Previous Close | 190.14 |
Day's Range | 175.61 - 185.00 |
52-Week Range | 175.61 - 275.00 |
Beta | undefined |
About CRL
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent r...
Analyst Forecast
According to 14 analyst ratings, the average rating for CRL stock is "Hold." The 12-month stock price forecast is $210, which is an increase of 17.75% from the latest price.
Next Earnings Release
Analysts project revenue of $985.03M, reflecting a -2.81% YoY shrinking and earnings per share of 2.54, making a 3.25% increase YoY.
2 months ago · businesswire.com
Charles River Launches New Retrogenix® Non-Human Protein LibraryWILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model select...